Gyre Therapeutics (GYRE) Competitors $9.49 +0.28 (+3.04%) Closing price 04:00 PM EasternExtended Trading$9.78 +0.29 (+3.00%) As of 06:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GYRE vs. PTCT, ADMA, ZLAB, RNA, OGN, ACLX, SWTX, RARE, AKRO, and ALVOShould you be buying Gyre Therapeutics stock or one of its competitors? The main competitors of Gyre Therapeutics include PTC Therapeutics (PTCT), ADMA Biologics (ADMA), Zai Lab (ZLAB), Avidity Biosciences (RNA), Organon & Co. (OGN), Arcellx (ACLX), SpringWorks Therapeutics (SWTX), Ultragenyx Pharmaceutical (RARE), Akero Therapeutics (AKRO), and Alvotech (ALVO). These companies are all part of the "pharmaceutical products" industry. Gyre Therapeutics vs. PTC Therapeutics ADMA Biologics Zai Lab Avidity Biosciences Organon & Co. Arcellx SpringWorks Therapeutics Ultragenyx Pharmaceutical Akero Therapeutics Alvotech Gyre Therapeutics (NASDAQ:GYRE) and PTC Therapeutics (NASDAQ:PTCT) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, community ranking, earnings and risk. Do insiders & institutionals have more ownership in GYRE or PTCT? 24.0% of Gyre Therapeutics shares are owned by institutional investors. 19.5% of Gyre Therapeutics shares are owned by insiders. Comparatively, 5.5% of PTC Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Do analysts rate GYRE or PTCT? PTC Therapeutics has a consensus target price of $64.00, indicating a potential upside of 13.74%. Given PTC Therapeutics' higher possible upside, analysts plainly believe PTC Therapeutics is more favorable than Gyre Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gyre Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00PTC Therapeutics 2 Sell rating(s) 4 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.53 Which has higher valuation and earnings, GYRE or PTCT? Gyre Therapeutics has higher earnings, but lower revenue than PTC Therapeutics. PTC Therapeutics is trading at a lower price-to-earnings ratio than Gyre Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGyre Therapeutics$105.76M8.40-$92.93M$0.05189.80PTC Therapeutics$806.78M5.50-$626.60M-$4.73-11.90 Does the media refer more to GYRE or PTCT? In the previous week, Gyre Therapeutics had 3 more articles in the media than PTC Therapeutics. MarketBeat recorded 13 mentions for Gyre Therapeutics and 10 mentions for PTC Therapeutics. PTC Therapeutics' average media sentiment score of 1.12 beat Gyre Therapeutics' score of 0.23 indicating that PTC Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gyre Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral PTC Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community prefer GYRE or PTCT? PTC Therapeutics received 567 more outperform votes than Gyre Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Gyre Therapeutics an outperform vote while only 61.87% of users gave PTC Therapeutics an outperform vote. CompanyUnderperformOutperformGyre TherapeuticsOutperform Votes1100.00% Underperform VotesNo VotesPTC TherapeuticsOutperform Votes56861.87% Underperform Votes35038.13% Is GYRE or PTCT more profitable? PTC Therapeutics has a net margin of -50.32% compared to Gyre Therapeutics' net margin of -84.57%. PTC Therapeutics' return on equity of 0.00% beat Gyre Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Gyre Therapeutics-84.57% -118.43% -71.97% PTC Therapeutics -50.32%N/A -16.44% Which has more volatility and risk, GYRE or PTCT? Gyre Therapeutics has a beta of 1.93, suggesting that its stock price is 93% more volatile than the S&P 500. Comparatively, PTC Therapeutics has a beta of 0.66, suggesting that its stock price is 34% less volatile than the S&P 500. SummaryGyre Therapeutics beats PTC Therapeutics on 10 of the 19 factors compared between the two stocks. Remove Ads Get Gyre Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GYRE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GYRE vs. The Competition Export to ExcelMetricGyre TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$888.38M$6.99B$5.68B$8.30BDividend YieldN/A2.72%4.55%4.02%P/E Ratio189.807.2324.5519.25Price / Sales8.40230.77395.7294.10Price / Cash50.4965.6738.1634.64Price / Book52.726.617.064.46Net Income-$92.93M$142.13M$3.19B$247.07M7 Day Performance10.74%2.79%1.49%3.05%1 Month Performance-17.37%2.70%5.87%-2.85%1 Year Performance-41.35%-4.42%14.94%4.63% Gyre Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GYREGyre Therapeutics0.1133 of 5 stars$9.49+3.0%N/A-47.6%$888.38M$105.76M189.8040High Trading VolumePTCTPTC Therapeutics3.4987 of 5 stars$57.17+4.9%$64.00+11.9%+96.0%$4.51B$806.78M-9.621,410Positive NewsADMAADMA Biologics2.4532 of 5 stars$18.67+1.3%$22.50+20.5%+223.1%$4.41B$426.45M66.68530Positive NewsZLABZai Lab2.3996 of 5 stars$38.35+0.4%$47.37+23.5%+120.5%$4.20B$398.99M-13.841,950Positive NewsRNAAvidity Biosciences1.874 of 5 stars$33.83+8.7%$66.69+97.1%+40.5%$4.07B$10.90M-11.75190OGNOrganon & Co.4.8578 of 5 stars$15.63+2.1%$20.80+33.1%-13.7%$4.03B$6.40B4.6910,000Positive NewsACLXArcellx2.2121 of 5 stars$72.74+1.5%$108.46+49.1%+3.2%$4.00B$107.94M-102.4580SWTXSpringWorks Therapeutics2.7593 of 5 stars$49.84-2.5%$73.20+46.9%-4.5%$3.73B$191.59M-14.32230Positive NewsRAREUltragenyx Pharmaceutical4.3754 of 5 stars$39.64+0.8%$91.71+131.4%-14.2%$3.67B$560.23M-6.251,276Positive NewsAKROAkero Therapeutics4.2234 of 5 stars$44.82+1.5%$76.29+70.2%+79.4%$3.57BN/A-11.9530ALVOAlvotech2.004 of 5 stars$11.31+0.1%$18.00+59.2%-22.7%$3.41B$391.87M-6.111,026Upcoming Earnings Remove Ads Related Companies and Tools Related Companies PTC Therapeutics Competitors ADMA Biologics Competitors Zai Lab Competitors Avidity Biosciences Competitors Organon & Co. Competitors Arcellx Competitors SpringWorks Therapeutics Competitors Ultragenyx Pharmaceutical Competitors Akero Therapeutics Competitors Alvotech Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GYRE) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gyre Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gyre Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GYRE Stock Free GYRE Stock Alerts